Page last updated: 2024-12-06

dexibuprofen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dexibuprofen is an enantiomer of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID). It is synthesized by chiral resolution of racemic ibuprofen, typically using enzymatic methods. Dexibuprofen exhibits a higher potency and longer duration of action compared to ibuprofen, primarily due to its preferential interaction with the COX-2 enzyme, which is involved in pain and inflammation. Dexibuprofen is studied extensively for its potential benefits in treating pain, inflammation, and other conditions, particularly those associated with COX-2 activity. Its higher potency and selectivity for COX-2 make it a promising candidate for developing new NSAIDs with improved efficacy and reduced side effects.'

dexibuprofen: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID39912
CHEMBL ID175
CHEBI ID43415
SCHEMBL ID43531
MeSH IDM0534105

Synonyms (138)

Synonym
smr000326688
MLS001066327
BRD-K14965640-001-03-3
atriscal
maxibufen syr
dolomin
maxibufen er
dexoptifen
dexibuprofen (usan/inn)
EU-0100654
D03715
BPBIO1_000830
PRESTWICK2_000907
NCGC00016861-01
lopac-i-4883
lopac-i-106
NCGC00015529-02
cas-51146-56-6
NCGC00015529-01
LOPAC0_000654
MLS001335879
MLS001335880
benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)-, (alphas)- (9ci)
d-ibuprofen
(+)-ibuprofen
(+)-(s)-p-isobutylhydratropic acid
dexibuprofen
benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)-, (alphas)-
(+)-ibuprophen
(s)-ibuprofen
(+)-alpha-methyl-4-(2-methylpropyl)benzeneacetic acid
(+)-(s)-ibuprofen
(s)-(+)-2-(4-isobutylphenyl)propionic acid
(s)-2-(p-isobutylphenyl)propionic acid
(s)-2-(4-isobutylphenyl)propanoic acid
(s)-2-(4-isobutylphenyl)propionic acid
(s)-(+)-ibuprofen
benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)-, (s)-
seractil
51146-56-6
(s)-(+)-4-isobutyl-alpha-methylphenylacetic acid
(alphas)-alpha-methyl-4-(2-methylpropyl)benzeneacetic acid
AB00513957
(2s)-2-(4-isobutylphenyl)propanoic acid
(s)-alpha-methyl-4-(2-methylpropyl)benzeneacetic acid
CHEBI:43415 ,
(s)-(+)-ibuprofen, reagentplus(r), 99%
SPBIO_002953
PRESTWICK0_000907
PRESTWICK1_000907
PRESTWICK3_000907
BSPBIO_000754
NCGC00094017-01
NCGC00094017-02
s(+)-ibuprofen
NCGC00015529-03
NCGC00016861-02
I-106
s-(+)-2-(4-isobutylphenyl)propionic acid
NCGC00016861-06
UNM-0000306099
(2s)-2-[4-(2-methylpropyl)phenyl]propanoic acid
bdbm50169047
(s)-2-(4-isobutyl-phenyl)-propionic acid
s-ibuprofen
CHEMBL175 ,
nsc-759814
I0549
HMS1570F16
s-(+)-ibuprofen
NCGC00094017-04
HMS2097F16
HMS3262C09
dtxsid9048724 ,
dtxcid6028650
tox21_113141
nsc759814
pharmakon1600-01502363
CCG-204740
HMS2231C07
AKOS015994628
NCGC00016861-05
NCGC00015529-11
NCGC00016861-03
CS-1393
dexibuprofenum
671dkg7p5s ,
dexibuprofene [inn-french]
nsc 759814
d-ibuproten
dexibuprofenum [inn-latin]
dexibuprofeno
dexibuprofen [usan:inn:ban]
dexibuprofene
unii-671dkg7p5s
dexibuprofeno [inn-spanish]
(s)-(+)-4-isobutyl-a-methylphenylacetic acid
AM20060649
LP00654
AKOS015890528
dexibuprofen [inn]
dexibuprofen [mart.]
benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)-, (s)-
dexibuprofen [usan]
dexibuprofen [who-dd]
HY-78131A
HEFNNWSXXWATRW-JTQLQIEISA-N
(s)(+) ibuprofen
(s)(+)ibuprofen
(s)-(+)-2-(4-isobutylphenyl) propionic acid
(2s)-2-[4-(2-methylpropyl)phenyl]propionic acid; (s)-(+)-4-isobutyl-alpha-methylphenylacetic acid; (s)-(+)-2-(4-isobutylphenyl)propionic acid
SCHEMBL43531
s (+) ibuprofen
HS-0088
tox21_500654
NCGC00261339-01
Q-200942
Q-200941
(s)-?-methyl-4-(2-methylpropyl)benzeneacetic acid
AB00513957_07
DB09213
sr-01000761395
SR-01000761395-2
sr-01000075945
SR-01000075945-1
HMS3714F16
benzeneacetic acid,|a-methyl-4-(2-methylpropyl)-,(|as)-
Q420051
SDCCGSBI-0050633.P002
NCGC00016861-13
ibuprofen-(s)
O10202
(s)-(-)-ibuprofen
dexibuprofen (free acid)
51146-56-6 (free acid)
A849905
EN300-180104
Z1508914616

Research Excerpts

Overview

Dexibuprofen is a non-steroidal analgesic and anti-inflammatory drug that is one of safest over the counter medications. It is an enantiomer of ib uprofen with low bioavailability which results from its hydrophobic nature.

ExcerptReferenceRelevance
"Dexibuprofen is a non-steroidal analgesic and anti-inflammatory drug that is one of safest over the counter medications. "( Synthesis of β-cyclodextrin hydrogel nanoparticles for improving the solubility of dexibuprofen: characterization and toxicity evaluation.
Ahmad, M; Khalid, Q; Minhas, MU, 2017
)
2.12
"Dexibuprofen is an enantiomer of ibuprofen with low bioavailability which results from its hydrophobic nature. "( Fabrication and characterization of dexibuprofen nanocrystals using microchannel fluidic rector.
Bashir, S; Isreb, M; Khan, J; Khan, MA; Mohammad, MA, 2018
)
2.2
"Dexibuprofen, is a practically water-insoluble nonsterodial anti-inflammatory drug which has a better anti-inflammatory effect than ibuprofen. "( Enhancement of solubility of dexibuprofen applying mixed hydrotropic solubilization technique.
El-Dein, EZ; El-Houssieny, BM; El-Messiry, HM, 2014
)
2.14
"Dexibuprofen is a pure S(+)-enantiomer product of racemic ibuprofen. "( Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers.
Bae, KS; Cho, SH; Choe, S; Ghim, JL; Jang, MJ; Jung, JA; Kim, UJ; Lim, HS; Noh, YH; Park, KM, 2011
)
2.04

Toxicity

ExcerptReferenceRelevance
" Gastrointestinal adverse drug reactions were reported in 8 patients (3."( Comparison of safety, efficacy and tolerability of dexibuprofen and ibuprofen in the treatment of osteoarthritis of the hip or knee.
Böttcher, E; Eller, N; Hawel, R; Mitterhuber, J; Rieger, JD; Stallinger, S; Zamani, O, 2014
)
0.65
"0 °C), the mean time when first normalization of body temperature, and the development of adverse events including gastrointestinal problem, elevated liver enzyme, and thrombocytopenia."( The antipyretic efficacy and safety of propacetamol compared with dexibuprofen in febrile children: a multicenter, randomized, double-blind, comparative, phase 3 clinical trial.
Choi, SJ; Choi, UY; Chun, YH; Jeong, DC; Kim, HM; Lee, J; Lee, JH; Moon, S; Rhim, JW, 2018
)
0.72
"Intravenous propacetamol may be a safe and effective choice for pediatric URTI patients presenting with fever who are not able to take oral medications or need faster fever control."( The antipyretic efficacy and safety of propacetamol compared with dexibuprofen in febrile children: a multicenter, randomized, double-blind, comparative, phase 3 clinical trial.
Choi, SJ; Choi, UY; Chun, YH; Jeong, DC; Kim, HM; Lee, J; Lee, JH; Moon, S; Rhim, JW, 2018
)
0.72
" In addition, rectal dexibuprofen did not increase the incidence of adverse outcomes, including bronchopulmonary dysplasia, intraventricular hemorrhage, sepsis, and necrotising enterocolitis."( Effectiveness and safety of rectal dexibuprofen versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants with gestational age<34 weeks: A pilot study.
Chen, XQ; Cui, SD; Pan, JJ; Yang, Y; Zhou, XG,
)
0.73
"Ibuprofen, a nonsteroidal anti-inflammatory drug, is considered a safe and effective analgesic for treating different types of pain and joint disorders."( Comparative Pharmacokinetics and Safety Studies of Dexibuprofen Injection and a Branded Product Ibuprofen Injection in Healthy Chinese Volunteers.
Hua, W; Su, M; Wang, M; Zhang, Q; Zhou, W; Zong, S, 2023
)
1.16

Pharmacokinetics

We aimed to compare pharmacokinetic. characteristics of controlled-release (CR) and immediate- release (IR) formulations of. dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers. Pharmacokinetic parameters of dexib uprofen were determined by noncompartmental analysis.

ExcerptReferenceRelevance
"To compare the pharmacokinetic (PK) profiles and bioequivalence of the extended-release (ER) and immediate-release (IR) formulations of dexibuprofen (DI) in healthy Chinese volunteers after single dose and multiple doses."( Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects.
Chen, M; H Chu, J; Ju, WZ; Liu, F; Liu, SJ; S Tan, H; Wu, T; Xiong, NN; Xu, MJ; Zhang, J; Zou, C, 2011
)
0.78
" Mean Cmax for ER and IR formulations were 22."( Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects.
Chen, M; H Chu, J; Ju, WZ; Liu, F; Liu, SJ; S Tan, H; Wu, T; Xiong, NN; Xu, MJ; Zhang, J; Zou, C, 2011
)
0.58
"We aimed to compare pharmacokinetic characteristics of controlled-release (CR) and immediate-release (IR) formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers."( Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers.
Bae, KS; Cho, SH; Choe, S; Ghim, JL; Jang, MJ; Jung, JA; Kim, UJ; Lim, HS; Noh, YH; Park, KM, 2011
)
0.8
" Pharmacokinetic parameters of dexibuprofen were determined by noncompartmental analysis."( Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers.
Bae, KS; Cho, SH; Choe, S; Ghim, JL; Jang, MJ; Jung, JA; Kim, UJ; Lim, HS; Noh, YH; Park, KM, 2011
)
0.88
"The pharmacokinetic parameters of single and multiple administrations of dexibuprofen did not differ for the IR and CR formulations in this small, selected group of healthy male Korean subjects."( Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers.
Bae, KS; Cho, SH; Choe, S; Ghim, JL; Jang, MJ; Jung, JA; Kim, UJ; Lim, HS; Noh, YH; Park, KM, 2011
)
0.83
" An in-vivo pharmacokinetic study was performed in six healthy human volunteers in comparison to the commercially available tablet of DXI."( Adoption of polymeric micelles to enhance the oral bioavailability of dexibuprofen: formulation, in-vitro evaluation and in-vivo pharmacokinetic study in healthy human volunteers.
Abdelbary, G; Makhlouf, A, 2014
)
0.64
" For the first time, in the present single-dose, randomized, open-label, 2-period crossover study, the safety and pharmacokinetic (PK) characteristics of a single-dose dexibuprofen injection (0."( Comparative Pharmacokinetics and Safety Studies of Dexibuprofen Injection and a Branded Product Ibuprofen Injection in Healthy Chinese Volunteers.
Hua, W; Su, M; Wang, M; Zhang, Q; Zhou, W; Zong, S, 2023
)
1.36

Bioavailability

Dexibuprofen is an enantiomer of ibuproen with low bioavailability. The purpose of this study was to use hydroxypropyl-β-cyclodextrin as a novel carrier in solid SNEDDS.

ExcerptReferenceRelevance
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
"The main objective of this study was to prepare a solid form of lipid-based self-emulsifying drug delivery system (SEDDS) by spray drying liquid SEDDS with an inert solid carrier Aerosil 200 to improve the oral bioavailability of poorly water-soluble drug dexibuprofen."( Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS).
Balakrishnan, P; Choi, HG; Hong, MJ; Jee, JP; Kim, JA; Kim, JO; Lee, BJ; Oh, DH; Woo, JS; Yong, CS; Yoo, BK, 2009
)
0.81
" The dissolution rate and bioavailability of dexibuprofen loaded in dry elixir were increased compared with those of dexibuprofen powder."( Dry elixir formulations of dexibuprofen for controlled release and enhanced oral bioavailability.
Kim, CK; Kim, JK; Kim, SR; Park, JS, 2011
)
0.93
"25% mannitol) showed higher Cmax and earlier tmax values than those of the commercial formula, where the relative bioavailability was calculated to be 160."( Adoption of polymeric micelles to enhance the oral bioavailability of dexibuprofen: formulation, in-vitro evaluation and in-vivo pharmacokinetic study in healthy human volunteers.
Abdelbary, G; Makhlouf, A, 2014
)
0.64
"Dexibuprofen is an enantiomer of ibuprofen with low bioavailability which results from its hydrophobic nature."( Fabrication and characterization of dexibuprofen nanocrystals using microchannel fluidic rector.
Bashir, S; Isreb, M; Khan, J; Khan, MA; Mohammad, MA, 2018
)
2.2
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" To enhance solubility and bioavailability of DEXI, DEXI-loaded solid dispersion (SD) was formulated."( Formulation of solid dispersion to improve dissolution and oral bioavailability of poorly soluble dexibuprofen.
Park, JS; Tran, P, 2021
)
0.84
"The purpose of this study was to use hydroxypropyl-β-cyclodextrin (HP-β-CD) as a novel carrier in solid SNEDDS and solid dispersions to enhance the solubility and oral bioavailability of poorly water-soluble dexibuprofen."( New potential application of hydroxypropyl-β-cyclodextrin in solid self-nanoemulsifying drug delivery system and solid dispersion.
Cheon, S; Choi, HG; Choi, YJ; Im, D; Ji, SH; Jin, SG; Kim, JO; Kim, JS; Lim, SJ; Oh, KT; Ud Din, F; Woo, MR; Youn, YS, 2021
)
0.81
" The solid dispersed granules and solid dispersion were compared in terms of powder property improvement, solubility increment and oral bioavailability enhancement of poorly water-soluble dexibuprofen."( Hydroxypropyl-β-cyclodextrin-based solid dispersed granules: A prospective alternative to conventional solid dispersion.
Cheon, S; Choi, HG; Giu Jin, S; Hun Ji, S; Jin Choi, Y; Lim, SJ; Oh Kim, J; Park, S; Ran Woo, M; Seok Youn, Y; Suk Kim, J; Ud Din, F, 2022
)
0.91
" However, their bioavailability is low and therefore, PLGA nanoparticles constitute a suitable approach to be administered as eyedrops."( Novel customized age-dependent corneal membranes and interactions with biodegradable nanoparticles loaded with dexibuprofen.
Camins, A; Esteruelas, G; Ettcheto, M; López, MLG; Muñoz-Juncosa, M; Ortiz, A; Prat, J; Pujol, M; Sánchez-López, E; Vega, E, 2023
)
1.12

Dosage Studied

The solid SEDDS could be used as an effective oral solid dosage form to improve the bioavailability of poorly water-soluble drug dexibuprofen. The results suggest that CDDE may be potential oral dosage forms to control the release.

ExcerptRelevanceReference
" Our results suggested that this solid SEDDS could be used as an effective oral solid dosage form to improve the bioavailability of poorly water-soluble drug dexibuprofen."( Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS).
Balakrishnan, P; Choi, HG; Hong, MJ; Jee, JP; Kim, JA; Kim, JO; Lee, BJ; Oh, DH; Woo, JS; Yong, CS; Yoo, BK, 2009
)
0.83
" Our results suggest that CDDE may be potential oral dosage forms to control the release and to improve the bioavailability of poorly water-soluble dexibuprofen."( Dry elixir formulations of dexibuprofen for controlled release and enhanced oral bioavailability.
Kim, CK; Kim, JK; Kim, SR; Park, JS, 2011
)
0.87
"This study found that in these subjects, the absorption rates of the two DI formulations were not bioequivalent, but at steady state, the daily exposure provided by less frequent DI ER dosing was not significantly different from the same daily dose with DI IR capsules, administered more frequently."( Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects.
Chen, M; H Chu, J; Ju, WZ; Liu, F; Liu, SJ; S Tan, H; Wu, T; Xiong, NN; Xu, MJ; Zhang, J; Zou, C, 2011
)
0.58
" The method was enantiomerspecific for the determination of dexibuprofen [S-(+)-isomer ibuprofen] in the presence of R-(-)-isomer ibuprofen in bulk drug, pharmaceutical dosage form and under stress degradation."( A validated enantioselective HPLC assay of dexibuprofen in dexibuprofen tablet formulations.
Aboul-Enein, HY; Awad, H; Lashin, S, 2012
)
0.88
" Also, impact of patch components on resulting tensile strength and in vitro permeation were used to predict an optimal patch formulation using a quality-by-design (QbD) approach, which was subsequently evaluated and further compared with a commercial oral tablet dosage form for in vitro and in vivo release (rabbit model)."( Formulation and evaluation of anti-rheumatic dexibuprofen transdermal patches: a quality-by-design approach.
Ahmad, Z; Akhlaq, M; Arshad, MS; Haj-Ahmad, R; Hussain, A; Kucuk, I; Mudassir, AM; Rasekh, M, 2016
)
0.69
"The contemporary work describes a rapid and cost effective reversed phase High Performance Liquid Chromatography (RP-HPLC) method for the quantification of Captopril, Lisinopril and Dexibuprofen (DXP) simultaneously in dosage formulations, active pharmaceutical ingredients and human serum."( Simultaneous determination of ACE inhibitors and dexibuprofen in active pharmaceutical ingredient, formulations and human serum by RP-HPLC.
Naveed, S; Qamar, F; Sana, A; Shakeel, S, 2017
)
0.9
" In future perspectives, these nanocrystals could be converted to solid dosage form and the process can be industrialized by chemical engineering approach."( Fabrication and characterization of dexibuprofen nanocrystals using microchannel fluidic rector.
Bashir, S; Isreb, M; Khan, J; Khan, MA; Mohammad, MA, 2018
)
0.76
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
ibuprofenA monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(2-methylpropyl)phenyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (35)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00040.003245.467312,589.2998AID2517
endonuclease IVEscherichia coliPotency0.25120.707912.432431.6228AID1708
thyroid stimulating hormone receptorHomo sapiens (human)Potency2.51190.001318.074339.8107AID926; AID938
regulator of G-protein signaling 4Homo sapiens (human)Potency0.94660.531815.435837.6858AID504845
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency22.38720.28189.721235.4813AID2326
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.31380.000229.305416,493.5996AID743075
arylsulfatase AHomo sapiens (human)Potency0.15101.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.00070.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00280.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
cytochrome P450 2C9 precursorHomo sapiens (human)Potency29.09410.00636.904339.8107AID883
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
lamin isoform A-delta10Homo sapiens (human)Potency2.51190.891312.067628.1838AID1487
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency29.09410.00638.235039.8107AID883
TAR DNA-binding protein 43Homo sapiens (human)Potency25.11891.778316.208135.4813AID652104
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency1.90120.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Acid-sensing ion channel 3Rattus norvegicus (Norway rat)IC50 (µMol)309.03009.50009.50009.5000AID1476081
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)8.38170.00032.177410.0000AID1704051; AID1704059; AID1704060; AID1704061; AID510444; AID643503
Aldo-keto reductase family 1 member C4Homo sapiens (human)IC50 (µMol)100.00002.30004.86338.2500AID703399
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)0.93450.00021.557410.0000AID405518; AID625243; AID642830
C-X-C chemokine receptor type 1Homo sapiens (human)IC50 (µMol)0.10000.00102.022710.0000AID248424
C-X-C chemokine receptor type 2Homo sapiens (human)IC50 (µMol)0.10000.00000.30296.0130AID248424
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)1.59500.00010.995010.0000AID1704052; AID642831
Aldo-keto reductase family 1 member C3Homo sapiens (human)IC50 (µMol)32.70000.05002.207010.0000AID703400
Aldo-keto reductase family 1 member C2 Homo sapiens (human)IC50 (µMol)42.40000.37004.09519.2800AID703401
Acid-sensing ion channel 1Rattus norvegicus (Norway rat)IC50 (µMol)346.73702.00002.00002.0000AID1476078
Prostaglandin G/H synthase 2Ovis aries (sheep)IC50 (µMol)133.50000.00101.453910.0000AID160734; AID510445
Aldo-keto reductase family 1 member C1Homo sapiens (human)IC50 (µMol)100.00000.00603.12657.9000AID703402
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GTP-binding protein (rab7)Canis lupus familiaris (dog)EC50 (µMol)4.77500.02201.21466.4190AID2036
ras protein, partialHomo sapiens (human)EC50 (µMol)30.00000.02000.22371.9660AID2038; AID2043
Rac1 proteinHomo sapiens (human)EC50 (µMol)30.00000.02025.986029.5100AID2039; AID2040
cell division cycle 42 (GTP binding protein, 25kDa), partialHomo sapiens (human)EC50 (µMol)11.50400.05633.055413.5100AID2021; AID2022
Ras-related protein Rab-2ACanis lupus familiaris (dog)EC50 (µMol)30.00000.15800.37770.7042AID2046
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)EC50 (µMol)30.00000.10601.07651.7000AID2038; AID2043
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (138)

Processvia Protein(s)Taxonomy
retinoid metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
bile acid biosynthetic processAldo-keto reductase family 1 member C4Homo sapiens (human)
steroid metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
androgen metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
bile acid and bile salt transportAldo-keto reductase family 1 member C4Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
cellular response to jasmonic acid stimulusAldo-keto reductase family 1 member C4Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
progesterone metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
dendritic cell chemotaxisC-X-C chemokine receptor type 1Homo sapiens (human)
cell surface receptor signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
receptor internalizationC-X-C chemokine receptor type 1Homo sapiens (human)
interleukin-8-mediated signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
chemokine-mediated signaling pathwayC-X-C chemokine receptor type 1Homo sapiens (human)
calcium-mediated signalingC-X-C chemokine receptor type 1Homo sapiens (human)
immune responseC-X-C chemokine receptor type 1Homo sapiens (human)
neutrophil chemotaxisC-X-C chemokine receptor type 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-X-C chemokine receptor type 1Homo sapiens (human)
dendritic cell chemotaxisC-X-C chemokine receptor type 2Homo sapiens (human)
chemotaxisC-X-C chemokine receptor type 2Homo sapiens (human)
inflammatory responseC-X-C chemokine receptor type 2Homo sapiens (human)
cellular defense responseC-X-C chemokine receptor type 2Homo sapiens (human)
signal transductionC-X-C chemokine receptor type 2Homo sapiens (human)
cell surface receptor signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cell population proliferationC-X-C chemokine receptor type 2Homo sapiens (human)
neutrophil chemotaxisC-X-C chemokine receptor type 2Homo sapiens (human)
receptor internalizationC-X-C chemokine receptor type 2Homo sapiens (human)
interleukin-8-mediated signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
neutrophil activationC-X-C chemokine receptor type 2Homo sapiens (human)
chemokine-mediated signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
calcium-mediated signalingC-X-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-X-C chemokine receptor type 2Homo sapiens (human)
immune responseC-X-C chemokine receptor type 2Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
G protein-coupled receptor signaling pathwayAldo-keto reductase family 1 member C3Homo sapiens (human)
response to nutrientAldo-keto reductase family 1 member C3Homo sapiens (human)
steroid metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of cell population proliferationAldo-keto reductase family 1 member C3Homo sapiens (human)
male gonad developmentAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to starvationAldo-keto reductase family 1 member C3Homo sapiens (human)
farnesol catabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
cyclooxygenase pathwayAldo-keto reductase family 1 member C3Homo sapiens (human)
keratinocyte differentiationAldo-keto reductase family 1 member C3Homo sapiens (human)
progesterone metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
retinal metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
macromolecule metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
regulation of retinoic acid receptor signaling pathwayAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionAldo-keto reductase family 1 member C3Homo sapiens (human)
testosterone biosynthetic processAldo-keto reductase family 1 member C3Homo sapiens (human)
renal absorptionAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to calcium ionAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to prostaglandin stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to corticosteroid stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to jasmonic acid stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to prostaglandin D stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
negative regulation of retinoic acid biosynthetic processAldo-keto reductase family 1 member C3Homo sapiens (human)
regulation of testosterone biosynthetic processAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of endothelial cell apoptotic processAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
G protein-coupled receptor signaling pathwayAldo-keto reductase family 1 member C2 Homo sapiens (human)
digestionAldo-keto reductase family 1 member C2 Homo sapiens (human)
steroid metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
positive regulation of cell population proliferationAldo-keto reductase family 1 member C2 Homo sapiens (human)
epithelial cell differentiationAldo-keto reductase family 1 member C2 Homo sapiens (human)
progesterone metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionAldo-keto reductase family 1 member C2 Homo sapiens (human)
cellular response to jasmonic acid stimulusAldo-keto reductase family 1 member C2 Homo sapiens (human)
cellular response to prostaglandin D stimulusAldo-keto reductase family 1 member C2 Homo sapiens (human)
Golgi organizationRas-related protein Rab-2ACanis lupus familiaris (dog)
protein transportRas-related protein Rab-2ACanis lupus familiaris (dog)
retinoid metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
xenobiotic metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
digestionAldo-keto reductase family 1 member C1Homo sapiens (human)
bile acid metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
bile acid and bile salt transportAldo-keto reductase family 1 member C1Homo sapiens (human)
intestinal cholesterol absorptionAldo-keto reductase family 1 member C1Homo sapiens (human)
epithelial cell differentiationAldo-keto reductase family 1 member C1Homo sapiens (human)
progesterone metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
retinal metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
cholesterol homeostasisAldo-keto reductase family 1 member C1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
response to organophosphorusAldo-keto reductase family 1 member C1Homo sapiens (human)
cellular response to jasmonic acid stimulusAldo-keto reductase family 1 member C1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (62)

Processvia Protein(s)Taxonomy
retinal dehydrogenase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member C4Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C4Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member C4Homo sapiens (human)
bile acid transmembrane transporter activityAldo-keto reductase family 1 member C4Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorAldo-keto reductase family 1 member C4Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
androsterone dehydrogenase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
5alpha-androstane-3beta,17beta-diol dehydrogenase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
testosterone dehydrogenase (NAD+) activityAldo-keto reductase family 1 member C4Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C4Homo sapiens (human)
chlordecone reductase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member C4Homo sapiens (human)
ketosteroid monooxygenase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
bile acid bindingAldo-keto reductase family 1 member C4Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
interleukin-8 receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
G protein-coupled receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
chemokine receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
protein bindingC-X-C chemokine receptor type 1Homo sapiens (human)
interleukin-8 bindingC-X-C chemokine receptor type 1Homo sapiens (human)
C-C chemokine receptor activityC-X-C chemokine receptor type 1Homo sapiens (human)
C-C chemokine bindingC-X-C chemokine receptor type 1Homo sapiens (human)
interleukin-8 receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
G protein-coupled receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
protein bindingC-X-C chemokine receptor type 2Homo sapiens (human)
C-X-C chemokine receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
interleukin-8 bindingC-X-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine bindingC-X-C chemokine receptor type 2Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C3Homo sapiens (human)
all-trans-retinol dehydrogenase (NAD+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorAldo-keto reductase family 1 member C3Homo sapiens (human)
phenanthrene 9,10-monooxygenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin D2 11-ketoreductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
geranylgeranyl reductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
ketoreductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin-F synthase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
15-hydroxyprostaglandin-D dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
androsterone dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
5alpha-androstane-3beta,17beta-diol dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
testosterone dehydrogenase (NAD+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
ketosteroid monooxygenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
Delta4-3-oxosteroid 5beta-reductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
bile acid bindingAldo-keto reductase family 1 member C3Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorAldo-keto reductase family 1 member C2 Homo sapiens (human)
phenanthrene 9,10-monooxygenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
carboxylic acid bindingAldo-keto reductase family 1 member C2 Homo sapiens (human)
bile acid bindingAldo-keto reductase family 1 member C2 Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
ketosteroid monooxygenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
indanol dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
androsterone dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
GTPase activityRas-related protein Rab-2ACanis lupus familiaris (dog)
GTP bindingRas-related protein Rab-2ACanis lupus familiaris (dog)
GDP bindingRas-related protein Rab-2ACanis lupus familiaris (dog)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member C1Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member C1Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member C1Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorAldo-keto reductase family 1 member C1Homo sapiens (human)
phenanthrene 9,10-monooxygenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
testosterone dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C1Homo sapiens (human)
carboxylic acid bindingAldo-keto reductase family 1 member C1Homo sapiens (human)
bile acid bindingAldo-keto reductase family 1 member C1Homo sapiens (human)
3beta-hydroxy-5beta-steroid dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptorAldo-keto reductase family 1 member C1Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
5alpha-androstane-3beta,17beta-diol dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
androsterone dehydrogenase (B-specific) activityAldo-keto reductase family 1 member C1Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C1Homo sapiens (human)
ketosteroid monooxygenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
indanol dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
androsterone dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (42)

Processvia Protein(s)Taxonomy
cytoplasmAldo-keto reductase family 1 member C4Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C4Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member C4Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C4Homo sapiens (human)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
plasma membraneC-X-C chemokine receptor type 1Homo sapiens (human)
secretory granule membraneC-X-C chemokine receptor type 1Homo sapiens (human)
external side of plasma membraneC-X-C chemokine receptor type 1Homo sapiens (human)
nucleoplasmC-X-C chemokine receptor type 2Homo sapiens (human)
plasma membraneC-X-C chemokine receptor type 2Homo sapiens (human)
cell surfaceC-X-C chemokine receptor type 2Homo sapiens (human)
microtubule cytoskeletonC-X-C chemokine receptor type 2Homo sapiens (human)
membraneC-X-C chemokine receptor type 2Homo sapiens (human)
secretory granule membraneC-X-C chemokine receptor type 2Homo sapiens (human)
mast cell granuleC-X-C chemokine receptor type 2Homo sapiens (human)
mitotic spindleC-X-C chemokine receptor type 2Homo sapiens (human)
external side of plasma membraneC-X-C chemokine receptor type 2Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
nucleusAldo-keto reductase family 1 member C3Homo sapiens (human)
cytoplasmAldo-keto reductase family 1 member C3Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C3Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member C3Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C3Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C2 Homo sapiens (human)
autophagosome membraneRas-related protein Rab-2ACanis lupus familiaris (dog)
acrosomal vesicleRas-related protein Rab-2ACanis lupus familiaris (dog)
endoplasmic reticulum membraneRas-related protein Rab-2ACanis lupus familiaris (dog)
endoplasmic reticulum-Golgi intermediate compartment membraneRas-related protein Rab-2ACanis lupus familiaris (dog)
melanosomeRas-related protein Rab-2ACanis lupus familiaris (dog)
cytosolAldo-keto reductase family 1 member C1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member C1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C1Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (153)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1704059Competitive inhibition of ovine COX-1 assessed as reduction in PGE2 level using 50 nM arachidonic acid as substrate preincubated with enzyme for 5 mins followed by substrate addition and measured after 20 mins by ELISA2020European journal of medicinal chemistry, Oct-15, Volume: 204Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core.
AID643437Drug level in ICR mouse brain at 10 mg/kg, po after 0.5 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID235360Selectivity ratio for cyclooxygenase II and cyclooxygenase I was determined2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Synthesis and evaluation of S-4-(3-thienyl)phenyl-alpha-methylacetic acid.
AID642834AUC (0 to infinity) in ICR mouse at 5 mg/kg, iv2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643433Drug level in ICR mouse brain at 5 mg/kg, iv after 2 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643428Plasma concentration in ICR mouse at 10 mg/kg, po after 8 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID1476079Inhibition of rat ASIC1a receptor expressed in xenopus lavies oocytes assessed as inhibition of pH 6.7-gated currents at 3 mM by two electrode voltage clamp relative to control2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen.
AID642842AUC (0 to t) in ICR mouse at 10 mg/kg, po2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643448Ratio of drug level in brain to plasma in ICR mouse at 5 mg/kg, iv after 6 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643426Plasma concentration in ICR mouse at 10 mg/kg, po after 4 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643431Drug level in ICR mouse brain at 5 mg/kg, iv after 0.5 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643438Drug level in ICR mouse brain at 10 mg/kg, po after 1 hr by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643418Plasma concentration in ICR mouse at 5 mg/kg, iv after 4 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643446Ratio of drug level in brain to plasma in ICR mouse at 5 mg/kg, iv after 2 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID642839Clearance in ICR mouse at 5 mg/kg, iv2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID251807Inhibition of CXCL8-induced chemotaxis of human polymorphonuclear cells at 10e-8 M2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
AID461506Inhibition of human recombinant COX2 activity at 500 uM by preincubation method2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Synthesis and evaluation of paracetamol esters as novel fatty acid amide hydrolase inhibitors.
AID642840Cmax in ICR mouse at 5 mg/kg, iv2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID162137In vitro inhibitory concentration against ram seminal vesicle prostaglandin G/H synthase 12004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Synthesis and evaluation of S-4-(3-thienyl)phenyl-alpha-methylacetic acid.
AID643429Drug level in ICR mouse brain at 5 mg/kg, iv after 0.083 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643441Drug level in ICR mouse brain at 10 mg/kg, po after 6 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID377717Dissociation constant, pKa of the compound2006Journal of natural products, Jul, Volume: 69, Issue:7
Chamazulene carboxylic acid and matricin: a natural profen and its natural prodrug, identified through similarity to synthetic drug substances.
AID1704060Competitive inhibition of ovine COX-1 assessed as reduction in PGE2 level using 250 nM arachidonic acid as substrate preincubated with enzyme for 5 mins followed by substrate addition and measured after 20 mins by ELISA2020European journal of medicinal chemistry, Oct-15, Volume: 204Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core.
AID643419Plasma concentration in ICR mouse at 5 mg/kg, iv after 6 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID642849Ratio of drug level in brain to plasma in ICR mouse at 10 mg/kg, po2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID642841Ratio of drug level in brain to plasma in ICR mouse at 5 mg/kg, iv2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID642835Mean residence time (0 to infinity) in ICR mouse at 5 mg/kg, iv2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643364Plasma concentration in ICR mouse at 5 mg/kg, iv after 2 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643503Inhibition of ovine COX1 by EIA2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID642838Apparent volume of distribution in ICR mouse at 5 mg/kg, iv2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643496Ratio of drug level in brain to plasma in ICR mouse at 10 mg/kg, po after 0.083 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID292958Inhibition of LOX12 by human platelet assay2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological activities of novel dexibuprofen tetraacetylriboflavin conjugates.
AID643500Ratio of drug level in brain to plasma in ICR mouse at 10 mg/kg, po after 2 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643436Drug level in ICR mouse brain at 10 mg/kg, po after 0.25 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID1476081Inhibition of rat ASIC3 receptor expressed in xenopus lavies oocytes assessed as inhibition of pH 6.4-gated currents by two electrode voltage clamp2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen.
AID510445Inhibition of sheep COX2 by spectrophotometry2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones.
AID643447Ratio of drug level in brain to plasma in ICR mouse at 5 mg/kg, iv after 4 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID1704061Competitive inhibition of ovine COX-1 assessed as reduction in PGE2 level using 1250 nM arachidonic acid as substrate preincubated with enzyme for 5 mins followed by substrate addition and measured after 20 mins by ELISA2020European journal of medicinal chemistry, Oct-15, Volume: 204Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core.
AID642848Oral bioavailability ICR mouse at 10 mg/kg2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID178383Effective dose for Anti-inflammatory activity was determined by carrageenan induced rat hind paw edema model2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Synthesis and evaluation of S-4-(3-thienyl)phenyl-alpha-methylacetic acid.
AID1476080Inhibition of rat ASIC2a receptor expressed in xenopus lavies oocytes assessed as inhibition of pH 4-gated currents at 1 mM by two electrode voltage clamp relative to control2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen.
AID248424Inhibition of CXCL8-induced chemotaxis in human polymorphonuclear cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
AID642846Tmax in ICR mouse at 10 mg/kg, po2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID1704054Inhibition of human recombinant 5-LOX assessed as reduction in LTB4 level using 800 uM arachidonic acid as substrate preincubated with enzyme for 10 mins followed by substrate addition and measured after 10 mins by ELISA2020European journal of medicinal chemistry, Oct-15, Volume: 204Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core.
AID643444Ratio of drug level in brain to plasma in ICR mouse at 5 mg/kg, iv after 0.5 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID703401Inhibition of human recombinant N-terminal His6-tagged AKR1C2 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3.
AID642844Mean residence time (0 to infinity) in ICR mouse at 10 mg/kg, po2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID377732Plasma concentration in human at 30 ug/mL by HPLC assay2006Journal of natural products, Jul, Volume: 69, Issue:7
Chamazulene carboxylic acid and matricin: a natural profen and its natural prodrug, identified through similarity to synthetic drug substances.
AID1704052Inhibition of human recombinant COX-2 assessed as reduction in PGE2 level using 10 uM arachidonic acid as substrate preincubated with enzyme for 5 mins followed by substrate addition and measured after 20 mins by ELISA2020European journal of medicinal chemistry, Oct-15, Volume: 204Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core.
AID643363Plasma concentration in ICR mouse at 5 mg/kg, iv after 1 hr by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643443Ratio of drug level in brain to plasma in ICR mouse at 5 mg/kg, iv after 0.25 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID160734In vitro inhibitory concentration against sheep placenta Prostaglandin G/H synthase 22004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Synthesis and evaluation of S-4-(3-thienyl)phenyl-alpha-methylacetic acid.
AID643502Ratio of drug level in brain to plasma in ICR mouse at 10 mg/kg, po after 6 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID703402Inhibition of human recombinant N-terminal His6-tagged AKR1C1 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3.
AID1704053Selectivity index, ratio of IC50 for ovine COX-1 to IC50 for human recombinant COX-22020European journal of medicinal chemistry, Oct-15, Volume: 204Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core.
AID643423Plasma concentration in ICR mouse at 10 mg/kg, po after 0.5 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643360Plasma concentration in ICR mouse at 5 mg/kg, iv after 0.083 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID643499Ratio of drug level in brain to plasma in ICR mouse at 10 mg/kg, po after 1 hr by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643424Plasma concentration in ICR mouse at 10 mg/kg, po after 1 hr by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID377718Lipophilicity, log D at pH 7.42006Journal of natural products, Jul, Volume: 69, Issue:7
Chamazulene carboxylic acid and matricin: a natural profen and its natural prodrug, identified through similarity to synthetic drug substances.
AID284871Inhibition of Fischer 344 rat brain acetylcholine esterase at 0.6 mM2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Design and study of some novel ibuprofen derivatives with potential nootropic and neuroprotective properties.
AID643434Drug level in ICR mouse brain at 5 mg/kg, iv after 4 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID703400Inhibition of human recombinant N-terminal His6-tagged AKR1C3 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3.
AID642847Cmax in ICR mouse at 10 mg/kg, po2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID642845Apparent half life in ICR mouse at 10 mg/kg, po2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID510446Selectivity index, ratio of IC50 for sheep COX1 to IC50 for sheep COX22010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones.
AID642830Inhibition of COX1 in human HEL 92.1.7 cells assessed as thromboxane B2 production incubated for 30 mins before arachidonic acid addition measured after 15 mins by ELISA2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643359Gastrointestinal toxicity in Wistar rat assessed as ulcerogenic effect at 100 mg/kg, po measured after 17 hrs post treatment (Rvb =0.50 +/- 0.41)2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID1704051Inhibition of ovine COX-1 assessed as reduction in PGE2 level using 10 uM arachidonic acid as substrate preincubated with enzyme for 5 mins followed by substrate addition and measured after 20 mins by ELISA2020European journal of medicinal chemistry, Oct-15, Volume: 204Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core.
AID307621Antiarthritic activity against Mycobacterium tuberculosis-induced rat arthritic model assessed as inhibition of chronic phase inflammation at 100 mg/kg relative to control2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Boswellic acids and glucosamine show synergistic effect in preclinical anti-inflammatory study in rats.
AID643425Plasma concentration in ICR mouse at 10 mg/kg, po after 2 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID642831Inhibition of COX2 in LPS-stimulated and PMA-treated human U937 cells assessed as PGE2 production after 15 mins by ELISA2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643440Drug level in ICR mouse brain at 10 mg/kg, po after 4 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID405518Inhibition of COX12008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Recent developments in fragment-based drug discovery.
AID618052Binding affinity to amyloid beta fibrils2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
Novel imaging agents for β-amyloid plaque based on the N-benzoylindole core.
AID642837Tmax in ICR mouse at 5 mg/kg, iv2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID510444Inhibition of sheep COX1 by spectrophotometry2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID643427Plasma concentration in ICR mouse at 10 mg/kg, po after 6 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643355Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 30 mg/kg, ig administered 1 hr before carrageenan challenge measured after 4 hrs post carrageenan challenge by plethysmometer2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643498Ratio of drug level in brain to plasma in ICR mouse at 10 mg/kg, po after 0.5 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID307617Antiinflammatory activity against carrageenan-induced paw edema in Wistar rat assessed as reduction of paw edema at 100 mg/kg relative to control2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Boswellic acids and glucosamine show synergistic effect in preclinical anti-inflammatory study in rats.
AID1476063Inhibition of rat ASIC1a receptor expressed in xenopus lavies oocytes up to 10 mM at greater than pH 5 by two electrode voltage clamp2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen.
AID1476078Inhibition of rat ASIC1a receptor expressed in xenopus lavies oocytes assessed as inhibition of pH 6.7-gated currents by two electrode voltage clamp2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen.
AID642836Apparent half life in ICR mouse at 5 mg/kg, iv2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643497Ratio of drug level in brain to plasma in ICR mouse at 10 mg/kg, po after 0.25 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643439Drug level in ICR mouse brain at 10 mg/kg, po after 2 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID307620Antiarthritic activity against Mycobacterium tuberculosis-induced rat arthritic model assessed as inhibition of acute phase inflammation at 100 mg/kg relative to control2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Boswellic acids and glucosamine show synergistic effect in preclinical anti-inflammatory study in rats.
AID643435Drug level in ICR mouse brain at 10 mg/kg, po after 0.083 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID284872Inhibition of Fe(2+)/ascorbate-induced lipid peroxidation in Fischer 344 rat hepatic microsomal membranes2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Design and study of some novel ibuprofen derivatives with potential nootropic and neuroprotective properties.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID643421Plasma concentration in ICR mouse at 10 mg/kg, po after 0.083 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643442Ratio of drug level in brain to plasma in ICR mouse at 5 mg/kg, iv after 0.083 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID642850Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 30 mg/kg intragastrically administered 1 hr before carrageenan challenge measured after 1 to 24 hrs post carrageenan challenge by plethysmometer2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643422Plasma concentration in ICR mouse at 10 mg/kg, po after 0.25 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID642833AUC (0 to t) in ICR mouse at 5 mg/kg, iv2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643356Analgesic activity in Swiss albino mouse assessed as inhibition of acetic acid-induced writhing at 30 mg/kg, ig administered 1 hr before acetic acid challenge measured 10 mins post acetic acid challenge2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID292954Antiproliferative activity against HT29 cells2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological activities of novel dexibuprofen tetraacetylriboflavin conjugates.
AID292955Antiproliferative activity against MCF7 cells2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological activities of novel dexibuprofen tetraacetylriboflavin conjugates.
AID643432Drug level in ICR mouse brain at 5 mg/kg, iv after 1 hr by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID703399Inhibition of human recombinant N-terminal His6-tagged AKR1C4 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3.
AID642851Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 33.6 mg/kg, ig administered 1 hr before carrageenan challenge measured after 1 to to 24 hrs post carrageenan challenge by plethysmometer2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID251770Inhibition of lipopolysaccharide-induced PGE-2 production at 10e-5 M2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
AID292957Inhibition of COX1 by human platelet assay2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological activities of novel dexibuprofen tetraacetylriboflavin conjugates.
AID643430Drug level in ICR mouse brain at 5 mg/kg, iv after 0.25 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID1476082Inhibition of rat ASIC3 receptor expressed in xenopus lavies oocytes assessed as inhibition of pH 6.4-gated currents at 3 mM by two electrode voltage clamp relative to control2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen.
AID461502Inhibition of ovine COX1 activity assessed as oxygen consumption at 50 uM by preincubation method2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Synthesis and evaluation of paracetamol esters as novel fatty acid amide hydrolase inhibitors.
AID643445Ratio of drug level in brain to plasma in ICR mouse at 5 mg/kg, iv after 1 hr by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643501Ratio of drug level in brain to plasma in ICR mouse at 10 mg/kg, po after 4 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643361Plasma concentration in ICR mouse at 5 mg/kg, iv after 0.25 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID643420Plasma concentration in ICR mouse at 5 mg/kg, iv after 8 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID510448Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan induced paw swelling at 70 mg/kg, po after 4 hrs2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones.
AID643362Plasma concentration in ICR mouse at 5 mg/kg, iv after 0.5 hrs by HPLC/MS/MS analysis2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID642843AUC (0 to infinity) in ICR mouse at 10 mg/kg, po2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.
AID510447Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan induced paw swelling at 70 mg/kg, po after 3 hrs2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (79)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's16 (20.25)29.6817
2010's46 (58.23)24.3611
2020's17 (21.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 71.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index71.27 (24.57)
Research Supply Index4.50 (2.92)
Research Growth Index6.12 (4.65)
Search Engine Demand Index119.19 (26.88)
Search Engine Supply Index2.03 (0.95)

This Compound (71.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (9.88%)5.53%
Reviews5 (6.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other68 (83.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]